Breast Cancer

The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.

Sexuality and intimacy issues often overlooked in breast cancer survivors.

Chronic inflammation causes cancer. Find out how and what's being done about it.

Cooling hot flashes brought on by cancer treatments.

Women ignite change across the globe.

Tamoxifen and antidepressants may not mix.

Fears can be magnified when a cancer diagnosis involves many unknowns, as is the case for triple-negative breast cancer.

Women from around the globe gathered at the Reach to Recovery International meeting to learn from others how to advocate for breast cancer survivors in their home countries.

After surgery, breast cancer patients are encouraged to exercise.

To learn more about managing cancer treatment-related hot flashes in men and women, CURE talked with Debra Barton, PhD, associate professor of oncology at the Mayo Clinic in Rochester, Minnesota.

There's now something to take aim at in triple-negative breast cancer.

What does Medicare cover when it comes to screening for colorectal cancer?

Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.

Newer targets found on cancer cells are providing scientists the ammunition to better treat cancer.

An infection reminds a breast cancer survivor that implants do not come with a lifetime guarantee.

Breast cancer patients facing reconstruction may not find all the answers they need.

Breast reconstructions may need to be redone years later.

News from the 2009 annual meeting of the American Society of Clinical Oncology.

Dennis Slamon, MD, PhD, talks about his involvement in the history of Herceptin.

Herceptin can cause cardiac toxicity

Dennis Slamon, MD, PhD, discusses HER2 and the development of Herceptin.

A timeline of important Herceptin developments.

Testing for HER2 overexpression in breast cancer can affect treatment decisions.

Adding Avastin (bevacizumab) to standard chemotherapy after surgery failed to extend the time early-stage colon cancer patients were free of recurrence.

For the first time, a test can predict which patients with stage 2 colon cancer are more likely to have a recurrence.

Adding Avastin to standard therapy delays progression of advanced HER2-negative breast cancer in women without prior treatment.

A large phase III study examining whether the addition of Tarceva (erlotinib) to Avastin (bevacizumab) delayed progression of advanced non-small cell lung cancer reached its primary goal.

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence.

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed.

A new class of drugs called PARP inhibitors is getting some serious attention in metastatic triple-negative breast cancers.